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Chronic kidney disease (CKD) is a major public health
problem. The classification of CKD by KDOQI and KDIGO and
the routine eGFR reporting have resulted in increased
identification of CKD. It is important to be able to identify
those at high risk of CKD progression and its associated
cardiovascular disease (CVD). Proteinuria is the most sensitive
marker of CKD progression in clinical practice, especially
when combined with eGFR, but these have limitations.
Hence, early, more sensitive, biomarkers are required.
Recently, promising biomarkers have been identified for CKD
progression and its associated CVD morbidity and mortality.
These may be more sensitive biomarkers of kidney function,
the underlying pathophysiological processes, and/or
cardiovascular risk. Although there are some common
pathways to CKD progression, there are many primary
causes, each with its own specific pathophysiological
mechanism. Hence, a panel measuring multiple biomarkers
including disease-specific biomarkers may be required. Large,
longitudinal observational studies are needed to validate
candidate biomarkers in a broad range of populations prior
to implementation into routine CKD management. Recent
renal biomarkers discovered include neutrophil gelatinase-
associated lipocalin, kidney injury molecule-1, and liver-type
fatty acid-binding protein. Although none are ready for use
in clinical practice, it is timely to review the role of such
biomarkers in predicting CKD progression and/or CVD
risk in CKD.
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Chronic kidney disease (CKD) is a major public health
problem affecting 13.5% of the adult Australian1 and 11% of
the US population.2 The introduction of kidney function
estimating equations3,4 and CKD classifications by the NKF
KDOQI (National Kidney Foundation Kidney Disease Out-
comes Quality Initiative5 and the KDIGO (Kidney Disease:
Improving Global Outcomes)6 have highlighted the condi-
tion and facilitated its diagnosis. Hence, early identification
of those likely to progress to end-stage renal disease (ESRD)
has become increasingly important. Existing measures such
as estimated glomerular filtration rate (eGFR) and protei-
nuria assist with this stratification.7,8 However, proteinuria
has limitations as a biomarker of CKD progression and
response to interventions.9 Therefore, new validated biomar-
kers are required for CKD progression and cardiovascular
disease (CVD) risk. Proteomic studies will provide data
regarding potential biomarkers in CKD10–12 but these must
be placed in clinical context.13,14 In view of recent develop-
ments in renal biomarker discovery, it is timely to review the
cross-sectional and longitudinal observational studies inves-
tigating these in CKD.
This review will first address biomarkers in CKD progres-
sion and, second, biomarkers of CVD in CKD. Biomarkers
are reviewed according to the main mechanisms they reflect
(see Table 1 and Figure 1), although there is some overlap.
Reviewed studies are summarized in Table 2. Biomarker
assay variability, reliability, and stability are beyond the scope
of this review.
BIOMARKER DEVELOPMENT AND TESTING IN PATIENTS
There are several clinical studies where biomarkers are
being tested. The CaNPREDDICT (Canadian Study of
Prediction of Risk and Evolution to Dialysis, Death and
Interim Cardiovascular Events Over Time) study is testing
biomarkers 6 monthly in 2500 prevalent patients with eGFR
15–45ml/min inB50 centers across Canada over 36 months.
The Spanish NEFRONA Project (Usefulness of imaging
techniques and novel biomarkers in the prediction of
cardiovascular risk in patients with CKD in Spain) is
recruiting 2661 patients and 843 controls into a prospective
observational study.15 Outcomes include cardiovascular
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events and mortality, carotid intima-media thickness, a
composite atherosclerosis score, and biomarkers.
Other studies include the MMKD (Mild to Moderate
Kidney Disease) study that recruited patients in Germany,
Austria, and South Tyrol16,17 and reported a range of
biomarkers.17–22 The CRIC (Chronic Renal Insufficiency
Cohort)23,24 and the CRIB (Chronic Renal Impairment in
Birmingham) study are both focusing on traditional and
nontraditional cardiovascular risk factors in CKD.25 CKD
studies have been reported from Japan,26 China,27 and
Germany (Cooperative Health Research in the Region
Augsburg (KORA) Study Group).28 Some of these have
measured multiple biomarkers.
STUDY CHARACTERISTICS AND SELECTION CRITERIA
Studies were identified through a systematic search of
PubMed using key terms: biomarkers, chronic kidney disease
and cardiovascular disease and papers were scrutinized for
additional references.
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: KIDNEY FUNCTION
Cystatin C
Cystatin C is a small molecule (13 kDa) that is filtered and
metabolized after tubular absorption.29,30 It is a sensitive
biomarker of kidney function in mild-to-moderate kidney
disease.31 In the MMKD study, serum cystatin C predicted
CKD progression.32 The 65 of 227 patients who progressed
over 7 years of follow-up had higher serum cystatin C at
baseline, suggesting that it is a promising biomarker of CKD
progression.32
b-Trace protein (BTP)
BTP is a lipocalin glycoprotein33,34 and a more sensitive
indicator of glomerular filtration than serum creatinine.35,36 It
has been proposed as an indicator of reduced GFR, particularly
in the ‘creatinine-blind’ range.35 However, others have shown
that BTP is inferior to cystatin C as an indicator of GFR.37 In a
report from the MMKD study group, BTP also provided
reliable risk prediction for CKD progression.32 Although
promising, BTP requires validation in large CKD populations.
Uric acid (UA)
Although not newly discovered, UA fulfils many criteria for a
validated biomarker in CKD. It is elevated in CKD and may
have a role in the pathophysiology of CKD progression
through endothelial dysfunction, vascular smooth muscle cell
proliferation, increased interleukin-6 (IL-6) synthesis, insulin
resistance, and impairment of nitric oxide production.38
Observational data indicate a relationship between serum UA
and CKD prevalence and progression.39–41 However, not all
studies have supported this contention.19 Although allopur-
inol lowers UA as well as improves renal function, a larger,
longer duration randomized controlled trial is required.38
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: KIDNEY STRUCTURE
Proteinuria
Increased urinary albumin excretion is an established
predictor of CKD progression42 and may reflect both
glomerular and tubulointerstitial injury. Analysis of data
from the Nord-Tryndelag Health Study found that combin-
ing microalbuminuria with eGFR improved the ability to
predict progression to ESRD.7 However, as a surrogate
Table 1 | Renal biomarkers according to the
pathophysiological process
Biomarker
Kidney function (GFR) Cystatin C
b-Trace protein
Tubulointerstitial injury NGAL
KIM-1
NAG
L-FABP
Glomerular injury Podocin
Nephrin
Podocalyxin
Endothelial dysfunction ADMA
Oxidative stress Ox-LDL
AOPP
TBARS
Plasma and urinary F2-isoprostanes
MDA
Protein reduced thiols
TAS
Protein carbonyls
AGE
Urinary 8-hydroxydeoxy guanosine
4-hydroxy-nonenal
Antioxidant enzyme activities (e.g.,
superoxide dismutase, glutathione
peroxidase, catalase)
GGT
Inflammation CRP and hs-CRP
PTX3
sTNFrii
IL-18
Tenascin
TIMP-1
Fibrosis TGF-b1
Cardiovascular dysfunction ANP
BNP and NT-proBNP
cTnT
Adrenomedullin
Metabolic disorders Adiponectin
FGF-23
ApoA-IV
Abbreviations: ADMA, asymmetric dimethylarginine; AGE, advanced glycation end
product; ANP, atrial natriuretic peptide; AOPP, advanced oxidation protein products;
ApoA-IV, apolipoprotein A-IV; BNP, brain natriuretic peptide; CRP, C-reactive protein;
cTnT, cardiac troponin T; FGF-23, fibroblast growth factor-23; GFR, glomerular
filtration rate; GGT, g-glutamyltransferase; hs-CRP, high-sensitivity-CRP; IL-18,
interleukin-18; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding
protein; MDA, malondialdehyde; NAG, N-acetyl-b-O-glucosaminidase; NGAL, neu-
trophil gelatinase-associated lipocalin; NT-proBNP, N-terminal brain natriuretic
peptide; Ox-LDL, oxidized low-density lipoproteins; PTX3, pentraxin 3; sTNFrii,
soluble tumor necrosis factor receptor II; TAS, total antioxidant status; TBARS,
thiobarbituric acid reactive substances; TGF-b1, transforming growth factor-b1;
TIMP-1, tissue inhibitor of metalloproteinases-1.
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marker of kidney damage, proteinuria has limitations,
particularly when assessing interventions in CKD that may
result in change in proteinuria.9 These limitations are based
on the differing etiologies of CKD and the associated
pathophysiological mechanisms responsible for the protei-
nuria in each case. In addition, the presence of proteinuria
itself may cause further kidney damage.43 Data from the
Alberta Province laboratory registry showed that for a
particular eGFR, increased proteinuria was associated with
the risk of CKD progression, myocardial infarction, and
mortality.8 Screening for microalbuminuria can detect early-
stage CKD and has been shown, using microsimulation
modeling, to be cost effective in patients with diabetes or
hypertension.44
Neutrophil gelatinase-associated lipocalin (NGAL)
NGAL, a ubiquitous lipocalin iron-carrying protein,45 is
highly expressed in the tubular epithelium of the distal
nephron and released from tubular epithelial cells following
damage such as acute kidney injury (AKI). It was originally
isolated from neutrophils46 but is also expressed in tissues
such as kidney, liver, epithelial cells,47,48 and vascular cells in
atherosclerotic plaques.49 It has multiple molecular
forms in the urine, one being dimeric originating from
neutrophils and the other monomeric from kidney tubular
epithelial cells.50 This difference has the potential to improve
the specificity of NGAL as a renal biomarker. Serum and
urinary NGAL have been identified as early biomarkers
of AKI.51–58
AKI is increasingly recognized as a prelude to CKD.59 In
an experimental study in rats, ongoing inflammation and
immune activity were found to be involved with the
pathogenesis of CKD, and NGAL was upregulated, suggesting
that it may be a valuable biomarker for the development of
CKD after AKI.60,61 Thus, there has been interest in NGAL as
a biomarker in CKD. In addition, recent evidence suggests
that NGAL may even be involved as a mediator of CKD
progression.62In fact, the NGAL (Lipocalin 2) knockout
mouse has markedly reduced renal lesions seen in CKD
progression.62 The same investigators in an associated
retrospective clinical study in patients with autosomal
dominant polycystic kidney disease found that an increase
in urinary NGAL was especially seen in those patients who
progressed more rapidly to end-stage kidney disease. Also, in
kidney tissue from patients with IgA nephropathy and
congenital nephron deficit, NGAL expression was increased
in renal tubules.
In a cross-sectional study of 80 nondiabetic patients with
CKD stages 2–4, serum NGAL was elevated, with the highest
levels seen in those with the most advanced CKD.63 Cross-
sectional studies in IgA nephropathy,64 autosomal dominant
polycystic kidney disease,65 glomerulonephritis,66 pediatric
lupus nephritis,67 and CKD68 have shown that urinary and
serum NGAL are increased across these diseases and may
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Figure 1 |Biomarkers of chronic kidney disease (CKD) progression and renal cardiovascular disease (CVD).
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Table 2 | Studies investigating biomarkers in the progression of CKD and associated comorbidities
Authors Biomarker Study population Study type Study duration Study outcomes
Horstrup et al.96 Tenascin and
TIMP-1
Renal outpatients, Berlin,
Germany (n=54)
Cross-sectional NA CKD patients had elevated serum and
urinary tenascin and TIMP-1 compared
with controls
Kamijo et al.90 u-L-FABP Renal biopsy patients from
St Marianna University
School of Medicine (n=50)
Cross-sectional NA u-L-FABP correlated with urinary protein
excretion and the degree of
tubulointerstitial damage on renal biopsy
Kamijo et al.91 u-L-FABP Nondiabetic CKD
patients (n=48)
Prospective observational 12 months u-L-FABP was a more sensitive biomarker
of CKD progression than proteinuria.
u-L-FABP increased with reduced
kidney function
Lee et al.158 GGT CARDIA study; African-
American and Caucasian
males and females (n=2478)
Prospective observational 15 years Serum GGT predicted microalbuminuria in
those with hypertension and diabetes
Tonelli et al.116 CRP and sTNFrii CARE study participants
with CKD (n=687)
Post hoc analysis of a
randomized controlled trial
58 months Increased CRP and sTNFrii at baseline
predicted greater eGFR decline
Ravani et al.101 ADMA CKD patients, Cremona,
Italy (n=131)
Prospective observational 7 months ADMA levels predicted development
of ESRD
Fliser et al.22 ADMA Nondiabetic CKD,
Germany, Austria, and
South Tyrol (n=227)
Prospective observational 52.8 months ADMA levels were significant predictors of
CKD progression to ESRD and doubling of
serum creatinine
Brunner et al.67 uNGAL Pediatric SLE nephritis
(n=35)
Cross-sectional NA uNGAL was significantly higher in SLE
patients than controls and correlated with
renal disease activity
Boes et al.17 ApoA-IV MMKD study, nondiabetic
CKD (n=177)
Prospective observational 47 years Increased ApoA-IV was associated with
increased CKD progression
Mitsnefes et al.68 sNGAL Pediatric CKD stages 2–4
(n=45)
Cross-sectional NA sNGAL correlated with cystatin C and both
correlated with measured GFR and eGFR.
NGAL outperformed cystatin C and eGFR
at lower levels of measured GFR
Ding et al.64 uNGAL and NAG IgA nephropathy, n=70
(40 Lee grade III, 30
Lee grade II)
Cross-sectional NA uNGAL increased in IgA Lee grade II
compared with controls. uNGAL was more
sensitive than NAG
Ryu et al.159 GGT Korean nondiabetic,
nonhypertensive males
(n=10,337)
Prospective observational 3.5 years Serum GGT a possible early predictor for
the development of CKD
Tong et al.121 PTX3 CKD stages 3 and 4
(n=71)
Post hoc analysis of a
prospective observational
NA PTX3 was negatively correlated
with eGFR
Bolignano et al.65 uNGAL and
sNGAL
ADPCKD (n=26) Cross-sectional NA uNGAL and sNGAL were elevated in
patients with ADPCKD compared with
controls and both correlated with kidney
function. Those with greater cyst
development had higher uNGAL and
sNGAL
Bolignano et al.66 uNGAL Glomerulonephritis
(proteinuria 41 g/day)
(n=33)
Cross-sectional NA uNGAL higher in glomerulonephritis
compared with controls and significantly
correlated with serum creatinine and
urinary protein excretion
Lajer et al.100 ADMA Type 1 diabetics with
CKD (n=397)
Prospective observational 11.3 years Plasma ADMA levels were associated with
progression of type 1 diabetic
nephropathy
Saraheimo et al.144 Adiponectin Finnish Diabetic
Nephropathy study, type I
diabetics (n=1330)
Prospective observational 5 years Adiponectin was associated with CKD
progression only in those with
macroproteinuria
Targher et al.160 GGT NHANES (n=13,188) Cross-sectional NA Increased GTT had a strong independent
relationship with CKD
Hanai et al.102 ADMA Japanese type 2 diabetics
with normoalbuminuria or
microalbuminuria (n=225)
Prospective observational 5.2 years Increased ADMA levels were associated
with increased risk of progression of
nephropathy
Teppala et al.161 GGT NHANES (n=9516) Cross-sectional NA No association between GGT and CKD
Bolignano et al.69 NGAL White Europeans with
CKD (n=96)
Prospective observational 18 months Baseline urinary and serum NGAL were
predictors of CKD progression
Nishida et al.71 Serum and
urinary NGAL
Pediatric kidney disease
(n=85)
Prospective observational 12 months Urinary NGAL was a superior marker of
CKD in children than serum NGAL
Spanaus et al.21 BNP and
NT-proBNP
MMKD study, nondiabetic
CKD (n=177)
Prospective observational 47 years Increased BNP and NT-proBNP both
predicted CKD progression
Dieplinger et al.20 ANP and ADM MMKD study, nondiabetic
CKD (n=177)
Prospective observational 47 years Increased ANP and ADM both predicted
CKD progression
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Table 2 | Continued
Authors Biomarker Study population Study type Study duration Study outcomes
Kiatchoosakun et al.198 cTnT Stage 3 and 4 CKD (n=103) Cross-sectional NA Increased cTnT was associated with
reduced kidney function
Levin et al.212 PTH, PO4, calcium CaNPREDDICT study, British
Columbia, Canada, eGFR
o30ml/min per 1.73m2
(n=4231)
Retrospective 4–31 months CKD progression was associated with
younger age, male gender, higher eGFR,
higher BP, PO4 and PTH levels, lower Hb
levels, and higher proteinuria
Sayers et al.213 Birth weight and
other biomarkersa
Aboriginal Childhood
Cohort Study (n=475)
Prospective cohort 11.4 years Birth weight was negatively correlated
with BP
Takamatsu et al.26 Urinary type IV
collagen and albumin
Community study, Arita,
Japan (n=1554)
Cross-sectional NA Albumin creatinine ratio was associated
with CKD in younger participants
Fakhrzadeh et al.118 CRP Kahrizak Elderly Study,
elderly Iranians (n=122)
Cross-sectional NA Combination of metabolic syndrome and
high CRP strongly associated with CKD risk
Waanders et al.77 Urinary KIM-1 Proteinuric non-diabetic
CKD (n=34)
Post hoc analysis
of randomized
controlled trial
6 weeks Urinary KIM-1 increased in nondiabetic
CKD and decreased with antiproteinuric
therapy
Keller et al.214 Ten inflammatory
and procoagulant
biomarkersb
Cardiovascular Health
Study (elderly) (n=4128)
Prospective cohort 7 years Baseline serum albumin associated with
rapid eGFR decline (43ml/min per
1.73m2 per year) in the elderly
Fox et al.117 CRP Jackson Heart Study, African
Americans (n=4320)
Cross-sectional NA CRP was associated with CKD
Manghat et al.137 FGF-23 South East Greater
London, UK,
Stage 1–4 CKD (n=145)
Cross-sectional NA FGF-23 was elevated in CKD stage 3 and
correlated with diabetes, serum
phosphate, and CRP
Hung et al.119 CRP polymorphisms AASK Study, African
Americans
CKD (n=642)
Prospective observational Range 3.5–6.5
years
CRP SNPs associated with higher CRP were
not associated with CKD progression. CKD
patients with the rs2808630_GG genotype
had a greater risk of progression
Nielsen et al.92 u-L-FABP Type 1 diabetics with
normoalbuminuria or
microalbuminuria (n=227)
Prospective observational 18 years High u-L-FABP predicted development
and progression of diabetic nephropathy
Tsioufis et al.103 CRP and ADMA Untreated essential
hypertensives (n=13,905)
Cross-sectional NA Elevated CRP and ADMA were associated
with microalbuminuria
Kern et al.84 Urinary NAG
pentosidine, AGE
fluorescence
DCCT trial type 1
diabetes (n=91)
Nested case–control 1–9 years Baseline urinary NAG predicted macro-
and micro-albuminuria. Baseline urinary
AGE predicted microalbuminuria
Spanaus et al.32 Serum BTP MMKD study, nondiabetic
CKD (n=177)
Prospective observational 47 years BTP along with serum creatinine and
cystatin C were reliable predictors of CKD
progression
Wu et al.72 uNGAL Drug-induced chronic
tubulointerstitial nephritis
(n=36)
Prospective observational 6–33 months Baseline uNGAL was predictive of renal
function decline
Kanbay et al.192 FGF-23 Gensini score in mild CKD
(n=177)
Cross-sectional NA FGF-23 was independently associated with
Gensini score, a measure of coronary
atherosclerosis
Zhou et al.131 Urinary CD14
mononuclear cells
Patients with ADPCKD (n=16) Prospective observational 2 years Baseline urinary CD14 mononuclear cells
showed a statistically significant
correlation with kidney volume in males
Vaidya et al.79 NAG and KIM-1 Patients with type 1 diabetes
mellitus (n=659)
Prospective observational 2 years Lower urinary levels of NAG and KIM-1
were associated with regression of
microalbuminuria
Viau et al.62 uNGAL Patients with ADPCKD (n=87) Retrospective 6 years Patients with higher urinary NGAL had
faster progression to end-stage
kidney disease
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; ADM, adrenomedullin; ADMA, asymmetric dimethylarginine; ADPCKD, autosomal
dominant polycystic kidney disease; AGE, advanced glycation end product; ANP, atrial natriuretic peptide; ApoA-IV, apolipoprotein A-IV; BNP, brain natriuretic peptide; BP,
blood pressure; BTP, b-trace protein; CaNPREDDICT study, Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time
study; CARDIA, Coronary Artery Risk Development in Young Adults; CARE, Cholesterol and Recurrent Events; CKD, chronic kidney disease, CRP, C-reactive protein; cTnT,
cardiac troponin T; DCCT, Diabetes Control and Complications Trial; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FGF-23, fibroblast growth factor-
23; GGT, g-glutamyltransferase; Hb, hemoglobin; KIM-1, kidney injury molecule-1; MMKD, Mild to Moderate Kidney Disease study; NA, not applicable; NAG, N-acetyl-b-O-
glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NHANES, National Health and Nutrition Examination Survey; NT-proBNP, N-terminal brain natriuretic
peptide; PO4, phosphate; PTH, parathyroid hormone; PTX3, pentraxin 3; SLE, systemic lupus erythematosus; sNGAL, serum NGAL; SNP, single-nucleotide polymorphism;
sTNFrii, soluble tumor necrosis factor receptor II; TIMP-1, tissue inhibitor of metalloproteinases-1; u-L-FABP, urinary liver-type fatty acid-binding protein; uNGAL, urinary NGAL.
aBlood pressure, total cholesterol, apolipoprotein A-1, apolipoprotein B, respiratory function, ultrasound kidney size, urinary albumin/creatinine ratio, fasting triglycerides,
insulin, and glucose.
bAlbumin, CRP, interleukin-6, intercellular adhesion molecule-1, white blood cell count, fibrinogen, factor VII, factor VIII, D-dimer, and plasmin-antiplasmin complex.
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reflect disease activity and kidney function. Baseline serum
and urinary NGAL were predictors of eGFR decline in a
longitudinal study in 96 patients with CKD from a range of
etiologies over a median follow-up period of 18.5 months.69
Both urinary and serum NGAL levels also increased in
parallel in a study of diabetic patients, suggesting that NGAL
may play an important role in the pathophysiology of renal
adaptation to diabetes and associated nephropathy.70 There
were significant correlations between serum and urinary
NGAL and eGFR and between the levels of urinary NGAL
and the degree of proteinuria in 85 pediatric patients with
CKD from a variety of etiologies.71 In a study of 36 patients
with drug-induced chronic tubulointerstitial nephritis, in-
creased urinary NGAL at baseline predicted decline in kidney
function.72 There is now strong evidence that increased
urinary and serum NGAL reflect damage across a spectrum
of kidney diseases73 as well as AKI and may predict
progression of CKD.69 The availability of more specific
assays that are able to detect the different forms of NGAL
may increase the specificity of urinary NGAL as a biomarker
in CKD.50
Kidney injury molecule 1 (KIM-1)
KIM-1 is a transmembrane tubular protein with uncertain
function, not detectable in the normal kidney, but elevated in
experimental and clinical kidney damage.74 KIM-1 expres-
sion is significantly increased within kidney biopsy tissue
collected from patients with kidney disease.74 It is increased
in the urine in AKI75and kidney disease,74 and is increased in
kidney transplant patients and associated with graft loss.76
Experimental studies suggest that KIM-1 may be an indicator
of AKI to CKD transition.60 A retrospective study in
proteinuric nondiabetic kidney disease patients found
elevated levels of urinary KIM-1.77 In addition, urinary
KIM-1 decreased with short-term antiproteinuric therapies.77
The diagnostic performance of KIM-1 in animal models as a
predictor of drug-induced kidney injury was recently
evaluated alongside more traditional serum creatinine and
blood urea nitrogen and urinary N-acetyl-b-O-glucosamini-
dase (NAG),78 where KIM-1 levels better correlated with the
degree of kidney tubular histopathology, suggesting that
KIM-1 measurement could facilitate elimination of poten-
tially nephrotoxic drug candidates. Lower urinary levels of
KIM-1 were associated with the regression of microalbumi-
nuria in patients with type 1 diabetes mellitus.79 Long-term
observational studies in larger populations are required to
assess urinary KIM-1 as a CKD biomarker.
N-Acetyl-b-O-glucosaminidase
NAG is predominantly a biomarker of proximal tubular
damage,80–83 but may also be a biomarker of injury to other
parts of the nephron. A nested case–control study from the
Diabetes Control and Compliance Trial found that baseline
urinary NAG predicted both micro- and macro-albuminuria
in type 1 diabetics.84 NAG is also elevated in the urine in
patients with glomerulonephritis compared with healthy
controls.85 A recent study in type 1 diabetes mellitus found
that lower levels of urinary NAG were associated with the
regression of microalbuminuria.79 It has not been assessed
longitudinally in CKD.
Liver-type fatty acid-binding protein (L-FABP)
L-FABP is expressed in proximal tubular cells and is a
biomarker of inflammation investigated in diabetes, diabetic
nephropathy, hypertension, and early CKD.86–90 Urinary
L-FABP (u-L-FABP) was correlated with the degree of
tubulointerstitial damage and urinary protein excretion in a
study of 50 patients with CKD.90 In a prospective study, u-L-
FABP was more sensitive than proteinuria in predicting CKD
progression.91 Baseline u-L-FABP predicted the development
of micro- and macro-albuminuria, independent of recog-
nized biomarkers, in 165 normoalbuminuric patients from a
cohort of 227 type 1 diabetics.92 In a recent intervention
study, pitavastatin 1mg per day reduced u-L-FABP in 30
CKD patients, which may reflect alleviation of tubulointer-
stitial damage.93
Tenascin and tissue inhibitor of metalloproteinases 1
Tenascin is a noncollagenous matrix protein involved in
interstitial renal pathology.94 Tissue inhibitor of metallopro-
teinases 1 has a role in inhibition of the degradation of
matrix and is upregulated in models of kidney disease.95
Compared with healthy controls, patients with CKD have
elevated serum levels of tenascin and tissue inhibitor of
metalloproteinases 1 (ref. 96). Urinary levels of these
molecules were also significantly raised but did not correlate
with the degree of proteinuria. At this stage, these molecules
are in the preliminary stages of assessment.
Glomerular injury: urinary nephrin, podocin, and podocalyxin
Although proteinuria is a feature of glomerular damage, new
biomarkers of kidney podocyte injury including urinary
nephrin, podocin, and podocalyxin have been discovered.97,98
Urinary nephrin and podocin are elevated in diabetic
nephropathy and active lupus nephritis. Increased urinary
podocalyxin is seen in IgA nephropathy, lupus nephritis, and
post-streptoccocal glomerulonephritis.99 Although promis-
ing, and perhaps more specific for glomerular disease, these
biomarkers require more detailed assessment before reaching
clinical utility.
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: ENDOTHELIAL DYSFUNCTION
Asymmetric dimethylarginine (ADMA)
ADMA is an amino acid that inhibits nitric oxide synthase
and, if present in increased quantities, results in decreased
nitric oxide production. Reduced nitric oxide production is
associated with endothelial dysfunction and kidney damage.
ADMA has been investigated as a biomarker in ESRD, but
more recently in CKD progression.100–102 In a study
investigating early CKD in type 1 diabetics, increased plasma
levels of ADMA were predictive of the development and
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progression of nephropathy.102 In another study, incident
CKD patients were followed prospectively where plasma
ADMAwas inversely correlated with GFR and was a predictor
of progression to ESRD.101 The progression of CKD was also
greater in another population of nondiabetic CKD patients
with elevated plasma ADMA levels.22 In a cross-sectional
study in patients with untreated hypertension, there was an
association between ADMA levels and the presence of
microalbuminuria and albumin/creatinine ratio.103
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: CARDIOVASCULAR PEPTIDES
Natriuretic peptides
Natriuretic peptides and adrenomedullin are important for
cardiovascular and kidney homeostasis and their effects
include natriuresis, hypotension, and diuresis.104,105 Na-
triuretic peptides have mainly been investigated as biomar-
kers in cardiac disease where elevated concentrations are
associated with poor prognosis, degree of left ventricular
dysfunction, and congestive cardiac failure.106–111 In CKD, N-
terminal pro-brain natriuretic peptide (pro-BNP), atrial
natriuretic peptide, and adrenomedullin levels have been
investigated in the MMKD study where high levels of each
were associated with CKD progression.20,21 In the first report
from these investigators, BNP and N-terminal pro-BNP were
measured in 177 nondiabetic CKD patients. Those patients
that reached an end point, defined as doubling of serum
creatinine or dialysis requirement, had significantly higher
BNP and N-terminal pro-BNP levels. However, after adjust-
ment for established predictors of CKD progression, only
BNP was predictive of reaching the combined end point.
Subsequently, these investigators measured plasma atrial
natriuretic peptide and adrenomedullin in the same popula-
tion and found that increased plasma concentrations also
predicted CKD progression.20 Hence, these biomarkers may
prove useful in determining CKD trajectory.21
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: INFLAMMATION AND FIBROSIS
There are increasing numbers of inflammatory and
fibrotic markers investigated in CKD and the key ones are
reviewed here.
C-reactive protein (CRP) and soluble tumor necrosis
factor (TNF) receptor II
CRP is a short pentraxin and an established biomarker of
inflammation in kidney disease.112,113 TNF-a is a proin-
flammatory mediator, which binds to soluble TNF receptors,
and plasma levels of TNF-a are increased in CKD.114,115
Soluble TNF receptor II is one such receptor, which is also an
inflammatory marker. A post hoc analysis of data from the
CARE (Cholesterol and Recurrent Events) trial showed that
increased plasma concentrations of CRP and soluble TNF
receptor II at baseline were independently associated with a
greater rate of kidney function decline.116 A cross-sectional
report from the Jackson Heart Study, a longitudinal
observational study conducted in African Americans, showed
that CRP was associated with the presence of CKD.117 Elderly
Iranians with the metabolic syndrome and high CRP levels
had significantly increased risk of CKD.118 Single-nucleotide
polymorphisms of CRP associated with higher CRP levels in
African Americans were not predictive of CKD progres-
sion.119 However, CKD patients with the rs2808630_GG
genotype had a greater risk of CKD progression. Increased
CRP levels were associated with microalbuminuria in
patients with untreated essential hypertension.103
Pentraxin-3 (PTX3)
PTX3 is a long pentraxin produced in response to
inflammatory signals by immune cells in contrast to CRP
that is produced by hepatic cells.120 In a study of 71 stage 3
and 4 CKD patients, there was an inverse relationship
between PTX3 and eGFR.121 The investigation of this
biomarker in CKD is in the very early stages.
Urinary IL-18
Urinary IL-18 is a biomarker of kidney tubular injury.122 In a
cross-sectional study, IL-18 was markedly increased in
patients with established AKI from ischemia, but not in
patients with AKI from urinary tract infection, CKD,
nephrotic syndrome, or those with prerenal failure.122,123
Urinary IL-18, more likely, offers prognostic information
regarding severity and mortality at the time of AKI diagnosis,
rather than indicating progression to CKD. However,
evidence that patients with diabetic nephropathy have renal
tubular cell overexpression of IL-18 may indicate that it
deserves further study in the context of CKD.124
Transforming growth factor-b1 (TGF-b1)
TGF-b1 is a healing modulator and if secretion is increased
there is accumulation of extracellular matrix and subsequent
fibrosis.125 Urinary TGF-b1 is increased in diabetic nephro-
pathy and glomerulonephritis.126,127 Serum TGF-b1 was
associated with risk factors for kidney disease in African
Americans, but not Caucasians.128 In a cross-sectional study,
urine concentrations of TGF-b1 were related to the severity of
diabetic nephropathy.129
CD14 mononuclear cells
In autosomal dominant polycystic kidney disease, where
there is great heterogeneity in disease progression, GFR is
known to be a poor indicator. Measurement of CD14 in the
urine correlates with total kidney volume in males, and hence
may prove to be a valuable early biomarker in this
disease.130,131
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: METABOLIC FACTORS
Fibroblast growth factor-23 (FGF-23)
FGF-23 is a hormone mediating phosphaturia and is
regulated by 1,25-dihydroxyvitamin D3. It suppresses 1a
hydroxylase activity in the proximal renal tubule.132 Serum
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concentrations of FGF-23 are elevated in early CKD and
ESRD.133,134 The cause of FGF-23 elevation in CKD is
unclear135 but, in early CKD, FGF-23 may rise before the rise
in serum phosphate.136 In a cross-sectional study of 145
patients with CKD stages 1–4, FGF-23 was found to be
associated with other indicators of CKD complications such
as diabetes, serum phosphate, and CRP. FGF-23 was elevated
more in stage 3 than stage 1 and 2 CKD.137 The phosphate
binder sevelemer reduced FGF-23 levels in early-stage CKD
patients with normal serum phosphate levels.138
Apolipoprotein A-IV
Apolipoprotein A-IV is a glycoprotein involved in cholesterol
transport and is increased in ESRD139 and earlier stages of
CKD.140 The MMKD study demonstrated that proteinuric
nondiabetic CKD patients with elevated apolipoprotein A-IV
had significantly faster CKD progression.17 The elevation of
apolipoprotein A-IV is reflective of kidney function and may
result from reduced renal catabolism.17
Adiponectin
Adiponectin is a hormone secreted by adipocytes141 and is
elevated in kidney disease.142,143 In the Finnish Diabetic
Nephropathy study, adiponectin levels were only predictive of
CKD progression in those with macroproteinuria, and not in
those with initial normoalbuminuria or microalbuminur-
ia.144 In this context, adiponectin could not be considered a
biomarker for early detection of CKD progression.
BIOMARKERS IN THE DIAGNOSIS OF CKD AND ITS
PROGRESSION: OXIDATIVE STRESS
Oxidative stress refers to the in vivo oxidation of lipids,
proteins, carbohydrates, and DNA, and it involves many
biochemical pathways. Hence, there are many compounds
called ‘biomarkers of oxidative stress’. Cross-sectional studies
have demonstrated that CKD patients have increased levels
of oxidative stress biomarkers.145–151 These studies have
compared CKD patients with matched controls145,147–149
and/or compared different CKD stages.145–147,149,150 Biomar-
kers have included plasma/serum measures of oxidized low-
density lipoproteins,145 advanced oxidation protein pro-
ducts,148 thiobarbituric acid reactive substances,148 protein
carbonyls,147,151 isoprostanes,147,150,151 protein reduced
thiols,147 total antioxidant status,150 4-hydroxy-nonenal,151
superoxide dismutase149 and glutathione peroxidise149 activ-
ities, urinary 8-hydroxydeoxy guanosine,149 and advanced
glycation end products.151 Advanced glycation end products
are associated with the development of diabetic nephro-
pathy.152 Pentosidine is an advanced glycation end product,
which may be present in the urine.153 In a nested case–control
study from the Diabetes Control and Compliance Trial,
baseline urinary pentosidine predicted macroalbuminuria
and baseline advanced glycation end product predicted
microalbuminuria.84
Findings from studies in CKD patients include: (1) oxidized
low-density lipoproteins are associated with endothelial
injury145 and inflammation,148 (2) elevated oxidative stress
occurs early in CKD,147 and increases as CKD progresses,150
and (3) patients with diabetic nephropathy147,151 and protei-
nuria149 have additional elevations of oxidative stress. Oxidative
stress increases further on renal replacement therapy145,146 and
regresses after kidney transplantation.154
Of most relevance to this review is the equivocal
relationship between eGFR and biomarkers of oxidative
stress. Two studies reported that oxidative stress was related
to kidney function,145,150 and one reported no link.147 This
difference may relate to the biomarkers measured and
highlights the complexity of oxidative stress assessment.
Future research should include the direct assessment of
reactant generation at the tissue level, use of multiple
biomarkers for a more comprehensive assessment of path-
ways involved, and longitudinal cohort studies assessing how
changes in these measures are related to outcomes such as
morbidity and mortality.
c-Glutamyl transpeptidase (GGT)
Until recently, the epidemiological associations of GGT were
unexplored.155 GGT has mainly been used as a marker of
liver disease and alcohol intake,156 but it has also been touted
as a biomarker of oxidative stress.157 In the CARDIA
(Coronary Artery Risk Development in Young Adults) study,
those with hypertension and diabetes had an association
between GGT (within the normal range) and the occurrence
of microalbuminuria.158 Ryu et al.159 reported, in a cohort of
nonhypertensive and nondiabetic Korean males, that GGT
may be an early predictor of CKD even when allowing for
confounding factors at baseline. In a cross-sectional analysis
of 13,188 adults in the NHANES (National Health and
Nutrition Examination Survey) 2001–2006, there was a strong
independent association between elevated GGT and CKD.160
Adjustment was undertaken for comorbidities, demo-
graphics, alcohol consumption, lipid-lowering therapy, the
presence of viral hepatitis, and laboratory results. However,
Teppala et al.161 reported cross-sectional data from NHANES
1999–2002 showing no association between increased GGT
levels and CKD when adjusted for age, gender, race, smoking,
alcohol consumption, diabetes, hypertension, obesity, and
serum lipids. The reasons for the differences between these
studies are unclear.
DISEASE-SPECIFIC BIOMARKERS
Although elements of CKD progression are common to all
underlying primary renal etiologies, there are specific
pathophysiological mechanisms linked to the primary renal
diseases underpinning the diagnosis of CKD. For this reason,
it is unlikely that a single biomarker will be able to predict
CKD progression when encompassing all primary renal
diseases. Disease-specific markers may supplement more
general biomarkers.
For instance, in idiopathic membranous nephropathy,
70% of patients from one study had the M-type phospho-
lipase A2 receptor identified in glomerular extracts, and
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the presence of antibodies against this antigen supported this
as important in the disease.162 In addition- single nucleotide
polymorphisms of the phospholipase A2 receptor 1 may
be involved in the etiology of idiopathic membranous
nephropathy.163,164
BIOMARKERS OF CVD MORBIDITY AND MORTALITY IN CKD
CVD is intimately associated with CKD and its progression,
and hence it is not surprising that there has been a keen
interest in searching for biomarkers that might predict
CVD morbidity and mortality in the CKD population. Along
with traditional risk factors, nontraditional risk factors
contribute to CVD in CKD. The next section reviews
biomarkers that have been investigated in the context of
predicting CVD morbidity and mortality in CKD. These
studies are summarized in Table 3.
Cystatin C
As plasma cystatin C is an accurate biomarker of kidney
function, and the latter is closely correlated with CVD risk, it
follows that plasma cystatin C would also be a biomarker of
CVD risk. Prospective studies have demonstrated an
increased CVD risk associated with increased plasma
cystatin C levels.165 In fact, in elderly individuals without
CKD, plasma cystatin C is a biomarker for the risk for CVD
and mortality166,167 and reflects coronary artery disease
severity.168 In patients with CKD, elevated plasma levels of
cystatin C are associated with all-cause mortality, cardiovas-
cular events, and incident heart failure.169 Plasma cystatin C
is, therefore, a powerful predictor of CVD and mortality in
those with and without CKD.
Uric acid
Although there are some observational data linking serum UA
with cardiovascular and all-cause mortality in the general
population, there is little information assessing this relation-
ship in CKD.170 Analysis of data from the ARIC (Athero-
sclerosis Risk In Communities) study found that although
there was an independent association between elevated serum
UA and mortality, there were no significant associations for
cardiovascular events and mortality in the CKD population.170
Natriuretic peptides
BNP was prospectively studied as a biomarker of cardiovas-
cular events in a CKD population in Japan, where the relative
risk of cardiovascular events was significantly higher in those
Table 3 | Studies investigating biomarkers in CVD morbidity and mortality in CKD
Authors Biomarker Study population Study type Study duration Study outcomes
Tong et al.121 PTX3 CKD stages 3 and 4 (n=71) Post hoc analysis of
prospective cohort
NA PTX3 was positively correlated with
cardiovascular events and mortality
Goicoechea et al.184 Fibrinogen CKD patients with eGFR
o60ml/min per 1.73m2
(n=128)
Prospective observational
longitudinal
5.5 years Serum fibrinogen predicted all-cause
mortality in CKD stages 3–5
Weiner et al.185 Fibrinogen, albumin,
triglyceride, and CRP
ARIC study participants, eGFR
60ml/min per 1.73m2
(n=1678)
Prospective cohort study 108 months Increased fibrinogen, triglyceride, CRP,
decreased albumin, predicted composite
events (MI, stroke, all-cause mortality)
Levin et al.212 PTH, PO4, calcium CaNPREDDICT study, British
Columbia, Canada, eGFR
o30ml/min per 1.73m2
(n=4231)
Retrospective 4–31 months Death associated with older age, lower BP,
Hb, higher PO4, PTH. Vitamin D associated
with reduced death
Lajer et al.100 ADMA Type 1 diabetics with CKD
(n=397)
Prospective observational 11.3 years Plasma ADMA levels predicted fatal and
nonfatal cardiovascular events
Ravani et al.101 ADMA CKD patients, Cremona, Italy
(n=131)
Prospective observational
study
27 months ADMA levels predicted mortality
Liabeuf et al.196 sTRAIL CKD stages 2–5 included 31%
CKD stage 5D (n=130)
Prospective cohort 20 months–2.1
years
sTRAIL inversely associated with mortality
Junyent et al.15 Multiple biomarkers NEFRONA Project Spain
(n=2661)
Prospective cohort
(in progress)
4 years Cardiovascular events, mortality, surrogate
vascular measures, and biomarkers
(in progress)
Sakuma et al.171 BNP Iwate-KENCO study, Ninohe,
Japan (n=15,394)
Prospective observational 2.8 years BNP a strong predictor of cardiovascular
events
Nielsen et al.92 u-L-FABP Type 1 diabetics with
normoalbuminuria or
microalbuminuria (n=227)
Prospective observational 18 years High u-L-FABP predicted mortality
Seiler et al.191 FGF-23 CKD patients not on
dialysis (n=149)
Prospective observational 4.8 years Elevated FGF-23 were predictive of
cardiovascular events
Rogacev et al.207 CD14++ and CD16+
monocytes
CKD patients not on
dialysis (n=119)
Prospective observational 4.9 years Presence of CD14++ and CD16+
monocytes were independently associated
with cardiovascular events
Abbreviations: ADMA, asymmetric dimethylarginine; ANP, atrial natriuretic peptide; ARIC, Atherosclerosis Risk In Communities; BP, blood pressure; BNP, brain natriuretic
peptide; CaNPREDDICT study, Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time; CARDIA, Coronary Artery
Risk Development in Young Adults; CKD, chronic kidney disease; CRP, C-reactive protein; cTnT, cardiac troponin T; CVD, cardiovascular disease; eGFR, estimated glomerular
filtration rate; FGF-23, fibroblast growth factor-23; GGT, g-glutamyltransferase; Hb, hemoglobin; MI, myocardial infarction; NA, not applicable; NHANES, National Health and
Nutrition Examination Survey; NT-proBNP, N-terminal brain natriuretic peptide; PO4, phosphate; PTH, parathyroid hormone; PTX3, pentraxin 3; sTRAIL, soluble tumor necrosis
factor-related apoptosis-inducing ligand; u-L-FABP, urinary liver-type fatty acid-binding protein.
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with the highest BNP levels.171 In children with CKD,
increased levels of BNP were associated with ventricular
hypertrophy with higher levels present in eccentric than
concentric hypertrophy, suggesting that BNP may be
predictive of abnormal cardiac geometry.172 The natriuretic
peptides have proven useful CVD biomarkers in the general
population and have potential for similar use in CKD
patients pending further studies.
Asymmetric dimethylarginine
ADMA is a biomarker of atherosclerosis173 and is associated
with increased blood pressure174 and insulin resistance.175 It
is a strong independent predictor of cardiovascular and
mortality risk in end-stage kidney disease,176 but has not
been as extensively investigated in predialysis CKD. In a
prospective study in 131 incident CKD patients followed for
a mean of 27 months, plasma ADMA levels were indepen-
dently predictive of total mortality.101 Also, in another
prospective observational study of type 1 diabetics with overt
nephropathy, plasma ADMA was predictive of both fatal and
nonfatal cardiovascular events.100 Further studies of this
biomarker in more diverse CKD populations are required.
Fibrinogen
Serum fibrinogen is a predictor of CVD events in the general
population,177–180 and is independently predictive of cardio-
vascular and all-cause mortality in end-stage kidney dis-
ease.181 This association has been demonstrated in patients
with CKD.182,183 More recent studies in patients with stage 3
and 4 CKD indicated that an elevated serum fibrinogen level
was an independent predictor of all cause mortality.184
Weiner et al.185 assessed nontraditional cardiovascular risk
factors including serum fibrinogen in stage 3 and 4 CKD
patients in both the ARIC and Cardiovascular Health studies
where increased serum fibrinogen was independently pre-
dictive of composite events that included myocardial
infarction, stroke, and all-cause mortality. Serum fibrinogen
may prove useful in a cardiovascular biomarker panel for
identifying CKD patients at risk of CVD.
Neutrophil gelatinase-associated lipocalin
Recent interest has focused on NGAL as a biomarker of CVD
as well as in AKI and CKD progression.186 This stems from
experimental187 and clinical evidence in the nonrenal
population.188,189 However, in a recent pilot study of 46
elderly patients with heart failure and eGFR 72.3±15.1ml/min
per 1.73m2, plasma NGAL levels increased in parallel with
predictive indicators of CVD, with plasma NGAL levels
4783 ng/ml correlating with CVD mortality after 2 years.190
NGAL may prove to be a useful biomarker of CVD associated
with CKD but studies in CKD populations are required.
Fibroblast growth factor-23
Elevated levels of FGF-23 have been shown to be predictive of
mortality in ESRD and cardiovascular events in CKD patients
before starting dialysis.191 A cross-sectional study in patients
with mild CKD found an independent association between
increased FGF-23 and the Gensini score, a measure of total
coronary atherosclerosis.192 Additional validation of this
association is required.193
Pentraxin-3
Only one study assessing PTX3 as a biomarker of CVD in
CKD was identified, where PTX3 was associated with
protein-energy wasting, inflammation, CVD, and all-cause
mortality in a study of 71 patients with stage 3 and 4 CKD.121
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)
TRAIL is a factor associated with protection against
inflammation and is involved with apoptosis194 and athero-
sclerosis.195 Liabeuf et al.196 assessed soluble TRAIL in 130
patients with stage 2–5 CKD that included 31% ESRD
patients. Soluble TRAIL was found to be a biomarker
associated with reduced inflammation and mortality.
Troponin T and I
Troponin T and I are sensitive biomarkers of cardiac injury in
the general population. Although mechanisms vary for
causation, increased plasma Troponin T and I, above the
cutoffs for a normal population, were independently
predictive of subsequent death in ESRD patients.197 Eleva-
tions in troponin T (cTnT) were frequent findings in patients
with stage 3 and 4 CKD and elevated cTnT has been
associated with reduced renal clearance.198 Elevated cTnT in
patients with CKD has also been shown to be because of
reduced renal clearance in patients with congestive heart
failure.199 However, detectable cTnT is associated with
reduced survival.200 The same investigators found cTnT and
cTnI elevated in CKD and that elevated cTnI was associated
with increased mortality.201 In addition, elevated levels of
cTnT and cTnI are seen frequently in patients with CKD
predialysis even in the absence of an acute coronary
syndrome. In fact, it has been shown that elevated levels of
cTnT measured in patients before starting dialysis predict
asymptomatic multivessel coronary artery stenosis.202 cTnT
and cTnI were found to be equivalent in differentiating short-
term prognosis in patients with CKD with non-ST-segment
elevation acute coronary syndromes but this was more useful
in those with more advanced CKD.203 Thus, despite
elevations in these biomarkers of CVD being seen associated
with reduced renal clearance, they are of use as biomarkers of
mortality risk in predialysis CKD patients.
Liver-type fatty acid-binding protein
In a prospective cohort study of 165 normoalbuminuric
type 1 diabetics, u-L-FABP was predictive of all-cause
mortality, independent of traditional risk factors such as
gender, age, smoking status, HbA1c, blood pressure, urinary
albumin excretion rate, and kidney function.92 Although this
study was not performed in the CKD population, it explored
progression to proteinuria and u-L-FABP may be worth
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assessing as a candidate biomarker of CVD and mortality in
CKD patients.
CD14þ þ CD16þ monocytes
Macrophages and monocytes are recognized participants in
the atherosclerotic process.204 Subsets of monocytes have
been identified based on the expression of different receptors
(lipopolysaccharide CD14 and FcgIII CD16) on their surface.
High counts of CD14þ þ CD16þ monocytes are increased
in inflammation205 and are also associated with the
development of cardiovascular events in the dialysis set-
ting.206 In a prospective study of 119 patients with predialysis
CKD from a range of etiologies, the presence of CD14þ þ
and CD16þ monocytes was associated independently with
cardiovascular events.207 At this stage, these results are purely
a stimulus for further investigation.
NEW BIOMARKER DEVELOPMENT
New biomarkers are usually identified from experimental
studies before investigation in clinical populations. Recently,
studies have investigated predictive biomarkers of acute
drug-induced kidney injury.78,208–210 For example, in a rodent
study of nephrotoxin-induced injury, urinary TFF3 (trefoil
factor 3) protein levels were markedly reduced, and urinary
albumin increased in association with tubular injury. In situ
hybridization of TFF3 mRNA also decreased in injured
tubules. Albumin outperformed serum creatinine and blood
urea nitrogen for detecting tubular injury, but TFF3
augmented the potential of blood urea nitrogen and serum
creatinine to detect kidney damage.210 The Nephrotoxicity
Working Group within the Critical Path Institute, a
pharmaceutical industry public–private partnership, sub-
mitted a recommendation to the US FDA (US Food and
Drug Administration) and the European Medicines Agency
for further study of seven urinary biomarkers of kidney
injury (KIM-1, albumin, total protein, b2-microglobulin,
cystatin C, clusterin, and trefoil factor 3), which qualified for
use in regulatory decision-making (Table 4). Most biomar-
kers in the panel showed better sensitivity and specificity than
blood urea nitrogen and serum creatinine, and all added
complementary information.211 Testing those not currently
assessed in CKD populations may prove fruitful. The
sequence of biomarker discovery and development through
to clinical utility is summarized in Figure 2.
SUMMARY
To enable nephrologists to focus on CKD patients that will
have a poor trajectory, we need better biomarkers that can
identify this earlier. Serum creatinine, eGFR, and proteinuria
are insensitive and reliance on these may result in extensive
time lapse where successful interventions could be tested and
applied. Some biomarkers reviewed show promise but
further validation is required in larger, more diverse
populations before translation into clinical practice. Of those
Table 4 | Summary of claims submitted to the FDA and EMEA on biomarkers associated with nephrotoxicity
Biomarker
Qualified
preclinically
Adds information
to SCr and BUNa,b
Outperforms SCr
and/or BUNa,b,c,d
Analytically
validated assay
Widely
available assay
Qualified for
clinical usee
KIM-1 Yes Yesa Yesa Yes Pending Yes
Albumin Yes Yesa Yesa Yes Yes Yes
CLU Yes Yesa Yesa Yes Yes Pending
TFF3 Yes Yesa No Yes Pending Pending
Total protein Yes Yesb Yesb,c Yes Yes Yes
Cystatin C Yes Yesb Yesb,c Yes Yes Yes
b2-Microglobulin Yes Yesb Yesb,c Yes Yes Yes
Abbreviations: BUN, blood urea nitrogen; CLU, clusterin; EMEA, European Medicines Agency; FDA, Food and Drug Administration; KIM-1, kidney injury molecule-1; SCr, serum
creatinine; TTF3, trefoil factor 3.
aAcute tubular alterations.
bAcute glomerular injury with acute tubular reabsorption impairment.
cBiomarker outperformed SCr.
dIf an inclusion receiver operating characteristic (ROC) analysis (true positive rate (sensitivity) against the rate of false positives (1–specificity) for a continuous variable against
a specific reference standard) analysis is considered, instead of an exclusion ROC analysis, cystatin C and b2-microglobulin outperform not only SCr but also BUN with respect
to the prediction of histopathologically confirmed kidney injury (see Honkanen et al.126 for further details of ROC analysis).
eQualified for clinical use refers to a ‘case-by-case’ on text and not to a broad general qualification.
Develop analytical
process (assay) to
measure biomarker
Evaluate
biomarker assay
Clinical validity to predict
renal function loss
Clinical utility of
biomarker assays
Regulatory approval
Clinical adoption
Biomarker identified from
experimental data
Biomarker proposed based
on clinical rationale
Preanalytical validity Analytical validity
Generalizability
Sensitivity
and specificity
Reference ranges Compare with
currently accepted
methods
• Stability
• Precision
• Limits of
  quantification
• Biological variability
  (e.g., diurnal)
• Effects of medications,
  food, types of food,
  smoking, exercise,
  so on
Figure 2 | Summary of biomarker discovery and development
through to clinical utility.
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reviewed, NGAL has the greatest promise as a biomarker of
CKD progression and cystatin C as a biomarker of kidney
function, CKD progression, and cardiovascular risk. It is
unlikely that a single marker will satisfy the requirement of
predicting CKD progression and cardiovascular morbidity
and mortality as it would be unlikely to reflect the
complexities of the multiple pathophysiological processes
involved in CKD progression or the underlying primary renal
disease. It is more likely that a focused panel of biomarkers
will be most rewarding.
In conclusion, the search for new relevant biomarkers to
better stratify patients with CKD according to the risk of
progression, morbidity, and mortality is underway. It is
important to determine whether the newly identified
biomarkers are purely associations or real biomarkers of
underlying pathophysiological processes. Testing biomarkers
prospectively in large, divergent populations over extended
follow-up periods, and validating them against hard outcome
measures such as the development of ESRD and mortality is
required before translation into clinical practice. Although
advances in proteomics technologies, sample conditioning,
and analysis methods have greatly improved productivity and
efficiency in biomarker discovery, biomarker verification and
validation remains a significant, costly, and high-risk under-
taking in the commercial development and deployment of
novel biomarkers for CKD.
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